PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN

Autor:	J.D. Cañete, A. López, S. Gómez, C. Peral, J. Nicolas, F. Rebollo, M. Vázquez, C. Gari
Rok vydání:	2019
Předmět:	Psoriatic arthritis Tofacitinib Cost effectiveness business.industry Health Policy Anti tumour necrosis factor Immunology Public Health Environmental and Occupational Health Medicine Tumor necrosis factor alpha business medicine.disease
Zdroj:	Value in Health. 22:S904
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.2646
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::50b85975a1995bb35f1c0808c130e391 https://doi.org/10.1016/j.jval.2019.09.2646 Zobrazit plný text záznamu Full Text from ScienceDirect